REGENXBIO's Upcoming Presentations at Major Ophthalmology Event
REGENXBIO Inc. (Nasdaq: RGNX) has exciting news for those interested in advancements in retinal disease treatments. The company will present interim data regarding the subretinal delivery of ABBV-RGX-314, an innovative gene therapy, at a significant ophthalmology annual meeting. This presentation is particularly important as it focuses on patients suffering from bilateral wet age-related macular degeneration (wet AMD), a condition affecting many individuals.
Understanding ABBV-RGX-314
ABBV-RGX-314 is a one-time AAV therapeutic under development in collaboration with AbbVie. AAV therapies have been hailed as groundbreaking approaches to treating various chronic retinal conditions, including not only wet AMD but also diabetic retinopathy. The goal of REGENXBIO is to harness the potential of gene therapy to offer long-lasting solutions to these debilitating diseases.
Details of the Presentations
New findings will be unveiled during the annual meeting, demonstrating the company's commitment to transparency and innovation in the field of gene therapy.
Title: Subretinal Delivery of Investigational ABBV-RGX-314 as a Gene Therapy for nAMD: First Time Results of a Fellow Eye Bilateral Dosing Study (abstract 30080148)
Presenter: Arshad Khanani M.D., M.A., FASRS, Director of Clinical Research at Sierra Eye Associates
Date/Time: Saturday, at 11:59 a.m. ET
The company will also showcase encore presentations, highlighting further research and findings.
Encore Presentations Overview
Title: A Phase 2 Dose-Escalation Study Evaluating Suprachoroidal Delivery of Investigational ABBV-RGX-314 Gene Therapy for DR (abstract 30078795)
Presenter: Arshad Khanani M.D., M.A., FASRS, Director of Clinical Research at Sierra Eye Associates
Date/Time: Monday, at 10:45 a.m. ET
Title: Long-Term Follow-Up Study Results from the Investigational Phase I/IIa ABBV-RGX-314 Subretinal Delivery Gene Therapy Program in nAMD (abstract 30079480)
Presenter: Philip P. Storey, M.D., Austin Retina Associates
Date/Time: Monday, at 12:45 p.m. ET
About REGENXBIO Inc.
Founded in 2009, REGENXBIO has established itself as a leader in the field of biotechnology, specifically focusing on gene therapy. The company emphasizes its mission to enhance quality of life through innovative gene therapy solutions, especially for rare and chronic diseases.
REGENXBIO’s pipeline includes not just ABBV-RGX-314, but also RGX-202 for treating Duchenne muscular dystrophy and RGX-121 for MPS II. With thousands of patients treated through its AAV Therapeutics platform, including treatments like ZOLGENSMA for spinal muscular atrophy, REGENXBIO is paving the way for one-time therapies that could revolutionize healthcare.
Contact Information
For inquiries, you can reach out to:
Dana Cormack - Corporate Communications
George E. MacDougall - Investor Relations
Frequently Asked Questions
What is REGENXBIO showcasing at the meeting?
REGENXBIO will present interim data on ABBV-RGX-314 for wet AMD and other chronic retinal conditions.
When will the presentations occur?
The presentations are scheduled for Saturday and Monday, with specific times for each session.
Who is the presenter for the main presentation?
Arshad Khanani M.D., a noted expert in clinical research, will lead the main presentation.
What is ABBV-RGX-314?
ABBV-RGX-314 is a gene therapy being developed to treat retinal conditions like wet AMD.
What is the vision of REGENXBIO?
REGENXBIO aims to lead in gene therapy innovation, focusing on improving lives through advanced treatments.
